BioLargo, Inc. (BLGO)
| Market Cap | 22.99M -55.2% |
| Revenue (ttm) | 4.08M -71.0% |
| Net Income | -14.49M |
| EPS | -0.05 |
| Shares Out | 331.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,726 |
| Open | 0.0725 |
| Previous Close | 0.0725 |
| Day's Range | 0.0672 - 0.0725 |
| 52-Week Range | 0.0675 - 0.1960 |
| Beta | -0.12 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies in the United States. The company’s technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances (PFAS) water contamination; advanced water and wastewater treatment; industrial odor and volatile organic compounds control, air quality control, and infection control; and myriad environmental remediation. It provides full-service environmental engineering, battery energy storage, and advanced antimicrobial medical device platf... [Read more]
Financial Performance
In 2025, BioLargo's revenue was $7.77 million, a decrease of -56.32% compared to the previous year's $17.78 million. Losses were -$11.78 million, 390.4% more than in 2024.
Financial StatementsNews
BioLargo Proxy statement: Proxy filing
BioLargo filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
BioLargo Subsidiary Clyra Medical to Exhibit at SAWC Fall 2026 in Las Vegas
Clyra and national launch partner Advanced Solution will feature ViaCLYR™, the copper-iodine wound irrigation solution, at the Symposium on Advanced Wound Care, October 15-18 WESTMINSTER, CA / ACCESS ...
BioLargo Earnings Call Transcript: Q2 2026
Despite a challenging year with a major revenue loss and market cap decline, the company advanced commercialization across its portfolio, secured new partnerships, and is relaunching its consumer products and medical segments. Lean capital allocation and strategic alliances position it for near-term growth.
BioLargo Quarterly report: Q2 2026
BioLargo has published its Q2 2026 quarterly earnings report on September 10, 2026.
BioLargo Earnings release: Q2 2026
BioLargo released its Q2 2026 earnings on September 10, 2026, summarizing the period's financial results.
BioLargo Canada, Fort McKay Oil Services enter partnership
BioLargo (BLGO) announced that it and its subsidiary BioLargo Canada have entered into a strategic partnership with Fort McKay Oil Services, a registered First-Nation company, combining the resources ...
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
Partnership backed by a conditional grant commitment from Emissions Reduction Alberta to in support of $4.6 CAD million project, with commercial trials already underway in northern Alberta WESTMINSTER...
BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time
WESTMINSTER, CA / ACCESS Newswire / September 9, 2026 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host ...
BioLargo subsidiary adds third distribution channel, accelerate ViaClyr rollout
BioLargo (BLGO) announced that its subsidiary Clyra Medical Technologies is expanding distribution of its FDA-cleared ViaClyr wound irrigation solution through a new Reseller Agreement with Spartan Me...
BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation Solution
Agreement with Spartan Medical opens adds a channel to the U.S. government healthcare market, supplementing existing U.S. commercial distribution and 18 foreign countries. WESTMINSTER, CA / ACCESS New...
BioLargo, Inc. to Present at the Inaugural Nasdaq / LD Micro Summit on September 9, 2026
WESTMINSTER, CA / ACCESS Newswire / September 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator and engineering services solution provider, today announced that Dennis P. ...
BioLargo to Participate in Gabelli Funds' 4th Annual PFAS Symposium in New York
Former U.S. EPA senior executive Sally Gutierrez will represent BioLargo at the investor event. WESTMINSTER, CA / ACCESS Newswire / August 25, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life ...
Gabelli To Host 4th Annual PFAS Symposium
PALM BEACH, Fla., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting its 4th Annual PFAS Symposium on September 24th, 2026, in New York City.
BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
Consumer Products Relaunch Set for October Under a Company-Owned Model; Clyra Medical Scaling Ahead of a Second Product Launch; Company to Host Stockholder Town Hall on September 10, 2026 WESTMINSTER,...
BioLargo's Lake Stockholm AEC Installation passes six months of PFAS remediation Topping Two Million Gallons
The patented AEC removes more than 99% of PFAS chemicals in water, consistently exceeding state and federal requirements, and generates a fraction of the waste of conventional methods. WESTMINSTER, CA...
BioLargo joins NJIT-led PFAS Partnership Innovation Consortium
BioLargo (BLGO) has joined the New Jersey PFAS Partnership Innovation Consortium an NJIT-led initiative focused on accelerating the development, validation, and deployment of PFAS technologies. BioLar...
BioLargo Joins New Jersey Institute of Technology-Led PFAS Consortium; President Tonya Chandler Appointed to Board of Directors
Company to contribute commercial PFAS treatment expertise alongside leading universities, regulators, utilities, and industry organizations advancing next-generation PFAS solutions. WESTMINSTER, CA / ...
BioLargo Equipment Solutions & Technologies' "PFAS Lady" to Teach PFAS 101 at 41st Annual Tri-State Seminar
Tonya Chandler will lead a seven-hour continuing education course for the fourth consecutive year at one of the water industry's largest regional gatherings WESTMINSTER, CA / ACCESS Newswire / July 29...
BioLargo PFAS Treatment Technology Featured in The Disruptive Quarterly
Company leaders join environmental attorneys, academic researchers, and industry innovators in a special issue on forever chemicals and the protection of clean water WESTMINSTER, CA / ACCESS Newswire ...
BioLargo preparing to relaunch CupriDyne-based consumer products
BioLargo (BLGO) is preparing to relaunch CupriDyne-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into...
BioLargo Relaunching CupriDyne(R)-Based Consumer Products - Back by Popular Demand and Generated More than $125 Million in Pet-Care Sales
BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the or...
BioLargo Engineering Unit Awarded $1.4 Million in U.S. Air Force Environmental Contract Renewals
BLEST Renews Air Quality Compliance Work at Five Air Force Bases Across New Mexico and Arizona WESTMINSTER, CA / ACCESS Newswire / July 1, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life scie...
BioLargo Quarterly report: Q1 2026
BioLargo has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioLargo Transcript: Status update
A strategic partnership with Aquatech is accelerating PFAS solution commercialization, with a robust pipeline and global engagement. Clyra is nearing a major product launch, while Cellinity advances battery tech and financing. Operational efficiency and IP protection remain priorities.
BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
Agreement Extends Clyra's International Reach Through One of the Region's Premier Healthcare Distributors WESTMINSTER, CA / ACCESS Newswire / May 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and...